ResMed Inc (RMD)

Currency in USD
191.26
+2.81(+1.49%)
Closed·
192.30+1.04(+0.54%)
·
RMD is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
190.16193.85
52 wk Range
180.27293.81
Key Statistics
Prev. Close
191.26
Open
191.53
Day's Range
190.16-193.85
52 wk Range
180.27-293.81
Volume
1.24M
Average Volume (3m)
1.37M
1-Year Change
-25.2628%
Book Value / Share
44.76
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
260.60
Upside
+36.25%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 14 consecutive years

ResMed Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

10 Buy
8 Hold
1 Sell
Ratings:
19 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 260.60
(+36.25% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
KeyBanc
Buy266.00+39.08%290.00MaintainJun 22, 2026
Morgan Stanley
Hold230.00+20.26%286.00DowngradeJun 17, 2026
Needham
Hold---MaintainMay 15, 2026
Baird
Hold225.00+17.64%254.00MaintainMay 01, 2026
Stifel
Hold235.00+22.87%265.00MaintainMay 01, 2026

ResMed Inc SWOT Analysis


Sleep Tech Dominance
ResMed's strong market position in sleep and respiratory care, driven by innovative products like AirSense 11, faces potential disruption from emerging GLP-1 drugs
Financial Resilience
Explore ResMed's impressive financial performance, with double-digit revenue growth and improved operating margins, despite challenges in gross margins
Market Expansion
Delve into ResMed's strategic moves beyond sleep apnea, targeting insomnia and COPD markets to diversify revenue streams and offset potential market share losses
Analyst Perspectives
Price targets range from $180 to $280, reflecting varied views on ResMed's ability to navigate challenges from GLP-1 drugs and increased competition
Read full SWOT analysis

ResMed Inc Earnings Call Summary for Q3/2026

  • ResMed Q3 FY2026 revenue rose 11% YoY to $1.43B, missing forecasts; EPS of $2.86 beat estimates by 1.78%, up 21% YoY on strong profitability.
  • Gross margin expanded 290 bps to 62.8%; operating margin improved 230 bps to 36.7%, driven by cost efficiencies and favorable product mix.
  • Masks and accessories segment drove growth with 12% global sales increase; company projects FY2026 gross margins between 62-63% with continued expansion.
  • Stock remained flat at $212 post-earnings, near 52-week low; management cited operational excellence and strategic high-margin product investments.
  • Company maintains 14-year dividend growth streak and aggressive buyback program; revenue shortfall attributed to market dynamics and pricing pressures.
Last Updated: 2026-04-30, 05:52 p/m
Read Full Transcript

Earnings

Latest Release
Apr 30, 2026
EPS / Forecast
2.86 / 2.81
Revenue / Forecast
1.4B / 1.42B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 10.37%
Dividend Yield
1.27%
Industry Median 1.68%
Annualized payout
2.40
Paid quarterly
5-Years Growth
+8.35%
Growth Streak

RMD Income Statement

Compare RMD to Peers and Sector

Metrics to compare
RMD
Peers
Sector
Relationship
P/E Ratio
18.2x22.4x−0.4x
PEG Ratio
1.110.900.00
Price/Book
4.3x1.7x2.6x
Price / LTM Sales
5.0x1.5x3.0x
Upside (Analyst Target)
25.5%0.0%57.3%
Fair Value Upside
Unlock3.5%8.9%Unlock

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
64.62M44.74%12.18B
Other Institutional Investors
47.82M33.11%9.01B
Public Companies & Retail Investors
31.98M22.14%6.03B
Total
144.42M100.00%27.22B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.8.50%12,279,3932,314,052
Vanguard Capital Management, LLC6.55%9,466,4161,783,946

People Also Watch

60.52
JEF
-3.65%
40.95
CTSH
-2.10%
466.11
AMP
-1.12%
152.38
LAMR
+0.42%
281.10
COR
+3.62%

FAQ

What Is the ResMed (RMD) Stock Price Today?

The ResMed stock price today is 191.26 USD.

What Stock Exchange Does ResMed Trade On?

ResMed is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for ResMed?

The stock symbol for ResMed is "RMD."

Does ResMed Pay Dividends? What’s The Current Dividend Yield?

The ResMed dividend yield is 1.25%.

What Is the ResMed Market Cap?

As of today, ResMed market cap is 27.62B USD.

What Is ResMed's Earnings Per Share (TTM)?

The ResMed EPS (TTM) is 10.37.

When Is the Next ResMed Earnings Date?

ResMed will release its next earnings report on Jul 30, 2026.

From a Technical Analysis Perspective, Is RMD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has ResMed Stock Split?

ResMed has split 4 times.

How Many Employees Does ResMed Have?

ResMed has 10600 employees.

What is the current trading status of ResMed (RMD)?

As of Jun 24, 2026, ResMed (RMD) is trading at a price of 191.26 USD, with a previous close of 191.26 USD. The stock has fluctuated within a day range of 190.16 USD to 193.85 USD, while its 52-week range spans from 180.27 USD to 293.81 USD.

What Is ResMed (RMD) Price Target According to Analysts?

The average 12-month price target for ResMed is 260.60 USD, with a high estimate of 325 USD and a low estimate of 180 USD. 10 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +36.25% Upside potential.

What Is the RMD After Hours Price?

RMD's last after hours stock price is 192.73 USD, the stock has decreased by 1.47, or 0.77%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.